[Serologic and skin test diagnosis of birch pollen allergy with recombinant Bet v 1, the chief allergen of birch].
BACKGROUND: Type I allergy represents a severe health problem in industrialized countries where up to 20% of the population suffers from allergic rhinitis, conjunctivitis and allergic asthma bronchiale and in severe cases from anaphylaxis, leading to death. OBJECTIVE: The aim of this study was to e...
Autors principals: | Menz, G, Dolecek, C, Schönheit-Kenn, U, Ferreira, F, Moser, M, Schneider, T, Suter, M, Boltz-Nitulescu, G, Ebner, C, Kraft, D, Valenta, R |
---|---|
Format: | Journal article |
Idioma: | German |
Publicat: |
1996
|
Ítems similars
-
Serological and skin-test diagnosis of birch pollen allergy with recombinant Bet v I, the major birch pollen allergen.
per: Menz, G, et al.
Publicat: (1996) -
Immunologic characterization of monoclonal antibodies that modulate human IgE binding to the major birch pollen allergen Bet v 1.
per: Lebecque, S, et al.
Publicat: (1997) -
High level expression of birch pollen profilin (Bet v 2) in Escherichia coli: purification and characterization of the recombinant allergen.
per: Susani, M, et al.
Publicat: (1995) -
The History and Science of the Major Birch Pollen Allergen Bet v 1
per: Heimo Breiteneder, et al.
Publicat: (2023-07-01) -
Preventive Administration of Non-Allergenic Bet v 1 Peptides Reduces Allergic Sensitization to Major Birch Pollen Allergen, Bet v 1
per: Oluwatoyin Akinfenwa, et al.
Publicat: (2021-10-01)